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Tumors can be placed into two categories: those that are
T cell-inflamed and those that are not, based on specific
chemokine and type I interferon gene expression signa-
tures and CD8+ tumor infiltrating T cells (TIL). That
these immune-inflamed tumors are not destroyed by the
CD8+ TIL argues that mechanisms must be present to
render the CD8+ TIL dysfunctional. Baseline infiltration of
CD8+ T cells appears to be critical for tumor regression in
response to neutralizing antibodies against CTLA-4 and
PD-L1, indicating that these immunotherapies work on
T cells in the tumor microenvironment. To better charac-
terize the functional properties and molecular targets
in dysfunctional TIL, we have applied knowledge from in
vitro T cell anergy studies towards an analysis of T cells in
the tumor microenvironment using several mouse tumor
models. These experiments led to the finding that
dysfunctional CD8+ TIL express the inhibitory receptors
PD-1 and LAG-3, but also paradoxically the co-stimulatory
molecules 4-1BB and OX-40. We therefore investigated
whether delivering positive signals through costimulatory
receptors, in combination with blockade of specific inhibi-
tory receptors, could act on dysfunctional TIL to restore
their function and induce tumor regression. We found
that an agonistic anti 4-1BB antibody combined with inhi-
bitory antibodies against either PD-L1, LAG-3 or CTLA-4
induce tumor regression of established B16.SIY tumors.
To test whether these combinations affect CD8+ T cells
in the tumor microenvironment or in the periphery we
measured the frequency of SIY reactive CD8+ T cells in
the tumor, the tumor-draining lymph nodes, and in the
spleen. We found that frequencies of SIY-reactive CD8+
T cells increased in both the periphery and the tumor
after these antibody combinations. To test if newly
primed cells from the periphery were required for
tumor regression, we used the S1P1 inhibitor FTY720 to
block T cell egress from lymph nodes. FTY720 treat-
ment given continuously beginning hours before these
antibody combinations did not prevent tumor control,
suggesting that the effects of combinations of agonist 4-
1BB antibody with inhibitory antibodies to CTLA-4,
PD-L1 or LAG-3 occur within the tumor microenviron-
ment. Effective combinations restored IL-2 production
by CD8+ T cells within the tumor site. Our data suggest
that reversing T cell dysfunction within the tumor
microenvironment may be a common mechanism of
multiple immunotherapy combinations, and that posi-
tive costimulatory signals can synergize with blockade
of inhibitory receptors to reverse TIL dysfunction and
support tumor regression.
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